Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Evolution of resistance during first-line treatment with boosted fosamprenavir is associated with baseline mutations.

AIDS (London, England) - 2 Jan 2006

Schürmann Dirk, Elston Rob, Xu Fan, Kleinkauf Niels, Wünsche Thomas, Suttorp Norbert

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiretroviral Therapy, Highly Active
Share to Carbamates
Share to Drug Therapy, Combination
Share to Furans

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HIV Protease Inhibitors

Share to Organophosphates

Share to Prodrugs

Share to Sulfonamides

Source

Identifiers

PMID: 16327339
DOI: 10.1097/01.aids.0000198080.32207.3c

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Evolution of resistance during first-line treatment with boosted fosamprenavir is associated with baseline mutations.PMID 16327339Read ↗

Primary mutations selected in vitro with raltegravir confer large fold changes in susceptibility to first-generation integrase inhibitors, but minor fold changes to inhibitors with second-generation resistance profilesSemantic proximity Read ↗

Rapid accumulation of HIV-1 thymidine analogue mutations and phenotypic impact following prolonged viral failure on zidovudine-based first-line ART in sub-Saharan Africa.Semantic proximity Read ↗

Evolution patterns of raltegravir-resistant mutations after integrase inhibitor interruptionSemantic proximity Read ↗

Population trends in the prevalence and patterns of protease resistance related to exposure to unboosted and boosted protease inhibitors.Semantic proximity Read ↗

Two possible pathways for acquisition of mutations related to nelfinavir resistance.Semantic proximity Read ↗

Monitoring the emergence of resistance mutations in patients infected with HIV-1 under salvage therapy with raltegravir in Rio de Janeiro, Brazil: a follow-up study.Semantic proximity Read ↗

Fostemsavir analog BMS-818251 has enhanced viral neutralization potency and similar escape mutation profile.Semantic proximity Read ↗

Evolution of HIV resistance during treatment interruption in experienced patients and after restarting a new therapy.Semantic proximity Read ↗

Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene.Semantic proximity Read ↗

Patterns of resistance emerging in HIV-1 from antiretroviral-experienced patients undergoing intensification therapy with tenofovir disoproxil fumarate.Semantic proximity Read ↗

8 EVOLUTION OF TREATMENT-EMERGENT RESISTANT VARIANTS IN TELAPREVIR PHASE 3 CLINICAL TRIALSSemantic proximity Read ↗

Evolution of antiretroviral phenotypic and genotypic drug resistance in antiretroviral-naive HIV-1-infected children treated with abacavir/lamivudine, zidovudine/lamivudine or abacavir/zidovudine, with or without nelfinavir (the PENTA 5 trial).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.